Daily Respiratory Research Analysis
Three impactful respiratory studies stood out: a nanobody-enabled, plug-and-display combination vaccine platform that safely protects animals against SARS‑CoV‑2, influenza, and RSV; a deep-learning system that detects ventilator circuit events in real time with high external performance; and a large pragmatic randomized trial showing inexpensive nasal sprays and a self-care website reduce respiratory illness burden over 12 months.
Summary
Three impactful respiratory studies stood out: a nanobody-enabled, plug-and-display combination vaccine platform that safely protects animals against SARS‑CoV‑2, influenza, and RSV; a deep-learning system that detects ventilator circuit events in real time with high external performance; and a large pragmatic randomized trial showing inexpensive nasal sprays and a self-care website reduce respiratory illness burden over 12 months.
Research Themes
- Modular multivalent vaccines for respiratory viruses
- AI-enabled real-time monitoring in mechanical ventilation
- Low-cost primary care interventions to reduce RTI burden
Selected Articles
1. Nanobody-based combination vaccine using licensed protein nanoparticles protects animals against respiratory and viral infections.
A single nanobody (P1-5B) bound recessed sites on licensed hepatitis E vaccine particles, enabling stable, noncovalent display of multiple respiratory virus antigens. Multivalent particles induced up to 3-log higher neutralizing titres versus soluble antigens and protected mice, hamsters, and non-human primates with a favorable safety profile.
Impact: Introduces a scalable, plug-and-display platform that overcomes antigen compatibility and formulation barriers for combination respiratory vaccines, with cross-species protection.
Clinical Implications: While preclinical, this platform could rapidly generate multivalent vaccines (e.g., combined influenza/RSV/COVID-19), potentially simplifying schedules and improving coverage pending human trials.
Key Findings
- Identified nanobody P1-5B that binds recessed, non-immunodominant sites on licensed HEV particles, enabling stable antigen display without disrupting native immunogenicity.
- Constructed multivalent particles displaying 5–11 antigens (SARS‑CoV‑2, influenza, RSV) with high-affinity assembly and preserved solubility.
- Achieved up to 3-log higher neutralizing titres versus soluble antigens and demonstrated robust protection in mice, hamsters, and non-human primates with favorable safety.
Methodological Strengths
- Rational binder discovery (alpaca immunization, phage display) and precise molecular engineering on a licensed particle scaffold.
- Efficacy demonstrated across multiple species, including non-human primates, supporting translational potential.
Limitations
- Preclinical only; no human immunogenicity, durability, or effectiveness data.
- Potential antigenic interference and manufacturing scale-up/regulatory pathways remain to be established.
Future Directions: First-in-human trials to assess safety, immunogenicity, and breadth; stability and cGMP manufacturing studies; expansion to pan-variant antigens and dosing optimization.
Combination vaccines promise to simplify immunization schedules and improve coverage, but remain technically challenging owing to antigen compatibility, immunogenic balance and formulation complexity. Here we report a modular strategy that uses a single-component nanobody binder to noncovalently attach diverse antigens to intact particles from the licensed hepatitis E vaccine. To identify a suitable binder, an alpaca was immunized with the vaccine, and nanobodies were screened via phage display. One nanobody, P1-5B, selectively bound recessed, non-immunodominant sites on the particle surface and enabled stable antigen display without disrupting native immunogenicity. Using this binder, we generated three vaccine formulations displaying five to eleven antigens, including variants from SARS-2 coronavirus, influenza virus and respiratory syncytial virus. These multivalent particles exhibited high-affinity assembly, preserved solubility and induced neutralizing titres up to three log units higher than soluble antigens. In mice, hamsters and non-human primates, the candidate vaccines conferred robust protection and showed a favourable safety profile. This approach introduces a scalable, plug-and-display system for rapid development of customizable combination vaccines.
2. Real-time detection of respiratory circuit events in mechanical ventilation using deep learning.
A convolutional neural network trained on ventilator waveforms detected fluid accumulation and leakage events with high internal and external performance. Circuit events were common and associated with airway pressure changes, suggesting potential for earlier, targeted interventions to prevent ventilator-associated complications.
Impact: Demonstrates generalizable, real-time detection of clinically relevant ventilator circuit events directly from waveform data, addressing a key monitoring gap that affects patient safety.
Clinical Implications: Integration into ventilator software or bedside analytics could prompt timely suctioning, circuit checks, or cuff adjustments, potentially reducing ventilator-associated events and improving respiratory mechanics.
Key Findings
- High performance detection of fluid-accumulation-like patterns (F1 99.90% internal; 92.35% external) and leakage (>99% accuracy).
- Circuit events were prevalent: 91.7% of patients had events; fluid-accumulation-like patterns in 77.1%, linked to median airway pressure increase of 2 cmH₂O.
- External validation on 30,528 breaths from independent patients demonstrated model generalizability.
Methodological Strengths
- Internal and external validation with detailed breath-level annotations.
- Clinically interpretable associations (airway pressure changes) support face validity.
Limitations
- Single-center patient source and limited patient number (48) may constrain heterogeneity.
- No prospective evaluation of clinical outcomes after algorithm deployment.
Future Directions: Prospective, multicenter implementation trials to assess impact on ventilator-associated events, alarm burden, and outcomes; regulatory-grade integration into ventilator firmware.
Respiratory circuit events, including fluid accumulation and circuit or cuff leakage during mechanical ventilation, increase ventilator-associated event risks but often go undetected. We developed a convolutional neural network analyzing 57,296 annotated breaths (26,768 training/internal validation; 30,528 external validation) from 48 patients. The algorithm detected fluid-accumulation-like patterns with an F1-score of 99.90% internally and 92.35% externally, while leakage detection exceeded 99% accuracy. Clinically, 91.7% of patients exhibited circuit events, with fluid-accumulation-like patterns observed in 77.1% of cases and associated with measurable airway pressure increases (median ΔPaw = 2 cmH₂O). The algorithm demonstrated high accuracy and generalizability in detecting respiratory circuit events from waveform data and may allow earlier intervention to reduce ventilator-associated complications through real-time detection.
3. 12 month follow-up of a randomised open label trial of nasal sprays and a behavioural intervention for respiratory tract infections (RTIs) in primary care.
In a large pragmatic four-arm randomized trial (~13,800 participants), both a commercial anti-viral nasal spray and isotonic saline reduced respiratory illness days over 12 months versus usual care, while a self-care website reduced incident infections. All interventions lessened symptom severity and work-days lost; saline also reduced antibiotic courses and practice visits.
Impact: Demonstrates sustained benefit of widely accessible, low-cost interventions to reduce RTI burden, with signals for reduced healthcare use and antibiotics, directly relevant to primary care and antimicrobial stewardship.
Clinical Implications: Consider recommending isotonic saline or antiviral nasal sprays and evidence-based self-care guidance during RTI seasons, especially for patients with recurrent illnesses, to reduce illness days, symptom severity, and work loss.
Key Findings
- Vick’s First-Defence and isotonic saline reduced respiratory illness days to 18 from 22 (IRR 0.84 and 0.83; both p<0.0001 vs usual care).
- The self-care website reduced incident infections (IRR 0.96; p=0.006) and all interventions lowered symptom severity and work-days lost.
- Isotonic saline was associated with fewer antibiotic courses and practice visits; in recurrent illness, saline most reduced recurrence and symptom days.
Methodological Strengths
- Large pragmatic randomized design with four parallel arms and 12-month follow-up.
- Clinically meaningful outcomes (illness days, severity, work loss) and antimicrobial stewardship-relevant measures.
Limitations
- Open-label design may introduce performance/reporting bias.
- Self-reported outcomes and differential adherence could affect estimates.
Future Directions: Head-to-head comparisons across age/risk strata, cost-effectiveness analyses, and implementation studies in diverse primary care settings.
BACKGROUND: The Immune defence trial documented short term impacts on RTIs for nasal sprays, and a stress-management and physical activity website. AIM: To estimate the impact of sprays and the website after 12 months. DESIGN: Four arm parallel randomised controlled trial Setting. Participants with co-morbidities and/or >=3 self-reported recurrent illnesses recruited by mailed invitation. Methods Participants were randomised by online software (stratified by recurrent illness and comorbidities) to i) usual care (n=3451) ii) Vick's First-Defence (VFD) spray (n=3448) (2 sprays/nostril, <=6x/day) iii) isotonic saline spray (n=3450) (same dosing) or iv) a website promoting physical activity and stress-management (n=3450). PRIMARY OUTCOME: respiratory illness days. FINDINGS: Usual care participants (n=3051) had on average 22 illness days, reduced by VFD ((n=3076; 18 days, adjusted incidence rate ratio (IRR) 0.84, 99% CIs 0.79,0.90; p<0.0001), and saline (n=3142; 18 days, IRR 0.83; 0.78,0.89; p<0.0001), but not the website (n=2811; 20 days, IRR 0.94;0.88,1.01, p=0.03)). The website reduced incident infections (0.96,0.93 to 0.99, p=0.006). All interventions reduced symptom severity and work-days lost, both spray groups reported lower intention to consult and fewer falls, and there were fewer antibiotic courses and practice visits with saline. Among those with recurrent illness saline had the most impact on both recurrence and symptom days (respectively 0.93 (0.87,0.99), 0.70 (0.60,0.82)). Headache were higher for VFD and lower for saline (7.8%, 3.4% respectively; 4.7% usual care). CONCLUSION: Widely available, inexpensive sprays and a website promoting self-care reduce the incidence, duration and/ or severity of RTIs and impact work-days lost and healthcare use.